Autologous Anti-Gp 100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
Skin Cancer
National Cancer Institute (NCI)Cell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
31 Active assets in the Skin Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Dana-Farber Cancer Institute | Phase 4 | BBB |
Cyclophosphamide Institute of Oncology Ljubljana | Phase 2 | BB |
Rapamycin Dana-Farber Cancer Institute | Phase 4 | BB |
Nivolumab 7 Hills Pharma, LLC | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Toray Industries, Inc | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Autologous Anti-Gp 100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →